Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

 As per the requirement of Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Pvt. Ltd a Category-I, Registrar & Share Transfer Agent (RTA), registered with the Securities and Exchange Board of India (SEBI) vide Registration Number: INR000004058 during the period April 1, 2021 to March 31, 2022 (both days inclusive).
08-04-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Princy AsatiDesignation :- Company Secretary and Compliance Officer
07-04-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018. This is for your information and records.
07-04-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window

 This is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated 2nd April 2019, Trading Window for dealing in Securities of the Company will remain closed for all Directors, Officers, Designated Persons of the Company and their immediate relatives with effect from Friday, 1st April 2022 till 48 hours after the declaration of Audited Financial Results of the Company for the Financial Year ended 31st March 2022. The date of meeting of Board of Directors to approve the Financial Results of the Company for the Financial Year ended 31st March 2022 shall be informed in due course. You are requested to kindly note the same.
29-03-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Kilitch Drugs (India) Limited has informed the Exchange about press release titled "Kilitch Drugs Commences Rs. 100 Crore New Facility Expansion Plan."
04-03-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Expansion Of Manufacturing Facility At Khopoli.

 Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we wish to inform you that our company has purchased a land, admeasuring approximately 15 Acres, at Village Maldev, Taluka: Pen, on Pen- Khopoli Highway to establish a green field pharma complex. Kilitch has been one of the prominent manufacturer for Injectables from more than 30 years. The time is ripe to get into the league of Biotech products to spur the growth. We plan to setup 4-6 manufacturing units in different therapeutics categories to cater to the growing demands Nationally and Internationally. All these manufacturing units will be built in line with our growth potential in Export Market.The project envisaged is futuristic and shall have maximum recognition of the world's leading regulatory authorities. The above is for information and dissemination to the public at large.
03-03-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Approval Of The Un-Audited Financial Results Of The Company For The Quarter Ended 31St December 2021;

 In continuation to our letter dated 7th February 2022, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 14th February, 2022, have - 1.Considered and approved the Un-audited financial results of the company for the quarter ended 31st December 2021; In this connection please find enclosed the copy of Un-audited Standalone & Consolidated financial Results of the Company for the quarter ended 31st December 2022 along with Limited Review Report by the Statutory Auditors of the Company as 'Annexure-I'. The meeting commenced at 04: 00 P.M. and concluded at 07:00 P.M. The above is for information and dissemination to the public at large.
14-02-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31St December, 2021

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve We wish to inform you that the meeting of the Board of Directors of the Company will be held on Monday, 14th February, 2022 at the Corporate Office of the Company at Mumbai at 04.00 P.M.: ?To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter ended 31st December, 2021; ?Any other matter with the permission of the Chair. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April, 2019 issued by NSE, the Trading Window has been closed with effect from Saturday, 1st January 2022 and shall continue to remain closed till 48 hours after the announcement of the financial results on 14th February, 2022.
07-02-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Allotment Of 5,00,000 Warrants Convertible Into Equity Shares To The Promoters Of The Company

 In furtherance to our letters dated December 15, 2021 and December 20, 2021 and in compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that Board Meeting of the Company held on January 24, 2022 has allotted 5,00,000 Warrants (1 Warrant convertible into 1 Equity Share of face value of Rs.10/- each) at a issue price of Rs. 177.15 (including premium of Rs. 167.15 per warrant) to the below mentioned persons/entities on preferential basis:- Sr. No. Name of allottees *Warrants (No) Category 1. Mr. Mukund Mehta 2,50,000 Promoter - Individual 2. Mr. Bhavin Mehta 2,50,000 Promoter - Individual Total 5,00,000 * 1 warrant will be converted into 1 equity share upon exercise of option by the warrant holder(s), within 18 months from the date of allotment of warrants. Consequently, the paid up equity share capital of the Company now stands increased from Rs. 15,58,23,190/- to Rs. 16,08,23,190/-.
24-01-2022
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation is given pursuant to Regulation 39(3) of SEBI (Listing obligations and disclosure requirement), Regulation 2015, regarding loss/ misplaced of share certificates by the following shareholder: Krishnan Rajan Folio No- 0012307 Certificate No- 27793 - 27793 No of shares- 100 Kindly take the above in your record and do the needful.
20-01-2022
Next Page
Close

Let's Open Free Demat Account